43 completed, 10 recruiting, 9 terminated, 9 unknown. 88 Phase 2, 33 Phase 1, 12 Phase 3.
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Exploring Ketamine's Effects on Depression and Anxiety in Adults With Low Vision Ketamine - Depression, Anxiety | Phase 2 | Not yet recruiting | Stanford University | 40 | 2027-01-01 | 2026-11-12 |
| Psilocybin for Amblyopia - Targeting Critical Periods in Humans Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin - Amblyopia | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 24 | 2026-11-01 | 2026-11-05 |
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Valproate for the Treatment of Residual Amblyopia Valproate, Placebo, Patch - Amblyopia, Amblyopia Unilateral | Phase 1 / Phase 2 | Recruiting | Boston Children's Hospital | 28 | 2026-07-01 | 2026-07-30 |
| Clinical Investigation of Safety and Effectiveness for the enVVe® System envve system - Chronic Venous Insufficiency, CVI | Phase 2 / Phase 3 | Not yet recruiting | Hancock Jaffe Laboratiores, Inc | 220 | 2026-07-01 | 2026-05-27 |
| Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration Ixo-vec - Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Phase 2 | Recruiting | Adverum Biotechnologies, Inc. | 15 | 2026-06-02 | 2026-08-05 |
| Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia Echothiophate Iodide 0.125% Ophthalmic Solution - Refractory Amblyopia | Phase 2 | Not yet recruiting | University of Oklahoma | 20 | 2026-06-01 | 2026-04-28 |
| Naturally Produced Cannabinoids for Neuroprotection From Concussion Broad spectrum cannabinoid formulation, Placebo gel capsule - Healthy | Phase 2 | Recruiting | University of Regina | 60 | 2026-06-01 | 2026-07-21 |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Active not recruiting | Laboratoires Thea | 81 | 2024-12-11 | 2026-07-09 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2025-05-02 |
| Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. Eyecyte-RPE™ - Retinal Disease, Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Eyestem Research Pvt. Ltd. | 54 | 2024-06-04 | 2024-09-24 |
| Docosahexaenoic Acid (DHA) Supplementation in Amblyopia Docosahexaenoic Acid, Placebo Oral Tablet - Amblyopia | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2024-01-01 | 2024-02-09 | |
| Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 Tirzepatide - Wolfram Syndrome | Phase 2 | Unknown | Ospedale San Raffaele | 10 | 2024-01-01 | 2024-02-22 |
| Alcohol Use Disorder and Cannabidiol Cannabidiol, Placebo - Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 180 | 2023-04-30 | 2026-06-15 |
| AMX0035 in Adult Patients With Wolfram Syndrome AMX0035 - Wolfram Syndrome | Phase 2 | Active not recruiting | Amylyx Pharmaceuticals Inc. | 12 | 2023-03-03 | 2026-04-14 |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] ADVM-022 - Neovascular Age-related Macular Degeneration | Phase 2 | Active not recruiting | Adverum Biotechnologies, Inc. | 69 | 2022-08-23 | 2026-10-27 |
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration Iptacopan (LNP023), Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | Novartis Pharmaceuticals | 168 | 2022-02-17 | 2026-10-27 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
Showing 20 of 88. Sign in to see all of them.
Eye Diseases (17) · Retinal Diseases (16) · Blindness (14) · Retinitis Pigmentosa (13) · Usher Syndromes (12) · Color Vision Defects (11) · Eye Diseases, Hereditary (11) · Macular Degeneration (11) · Amblyopia (10) · Eye Abnormalities (9) · Retinal Degeneration (6) · Wet Macular Degeneration (6) · Hemianopsia (5) · Photophobia (5)
Nervous System Diseases (87) · Neurologic Manifestations (84) · Pathological Conditions, Signs and Symptoms (84) · Sensation Disorders (84) · Signs and Symptoms (83) · Eye Diseases (71) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (30) · Eye Diseases, Hereditary (27) · Genetic Diseases, Inborn (26) · Brain Diseases (25) · Central Nervous System Diseases (25) · Blindness (24) · Ear Diseases (23) · Hearing Disorders (23)
Ranibizumab (6) · Intravitreal Injections (4) · salicylhydroxamic acid (4) · Valproic Acid (3) · Dexamethasone (2) · aflibercept (2) · nitisinone (2) · 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid (1) · 4-phenylbutyric acid (1) · Acetaminophen (1) · Acetazolamide (1) · Aspirin (1) · Atropine (1) · Blood Specimen Collection (1) · Bupivacaine (1)
Laboratoires Thea (6) · Novartis Pharmaceuticals (4) · ProQR Therapeutics (4) · University of Magdeburg (4) · Adverum Biotechnologies, Inc. (3) · Johns Hopkins University (3) · US Department of Veterans Affairs (3) · Beacon Therapeutics (2) · MeiraGTx UK II Ltd (2) · National Eye Institute (NEI) (2) · Pfizer (2) · Sanofi (2) · Shahid Beheshti University of Medical Sciences (2) · University of Birmingham (2) · AAVantgarde Bio Srl (1)
United States (56) · United Kingdom (15) · Germany (12) · Canada (10) · France (10) · Italy (5) · Spain (5) · Belgium (4) · Netherlands (4) · Puerto Rico (4) · Brazil (3) · Austria (2) · Denmark (2) · Iran (2) · Poland (2)
Nancy Rocheleau, Program Analyst (3) · Adam Turpcu, PhD (2) · David Jacobs, MD, MBA (2) · John Fryer, Ph.D., Asst. Director (2) · Agnes Wong, MD (1) · Alan B Scott, MD (1) · Alan Lankford, PhD (1) · Alan R. Spitzer, MD (1) · Alexander Foss, BA BMBCh MRCP MRCOphth FRC (1)
PMID 37314061, PMID 10654946, PMID 20126486, PMID 20212198, PMID 20837811, PMID 22828504, PMID 23688108, PMID 24504128, PMID 24705452, PMID 24756302, PMID 24756514, PMID 24781936, PMID 25205868, PMID 25370510, PMID 25370513, PMID 25678831, PMID 26024112, PMID 26335066, PMID 26618282, PMID 26778344, PMID 26857842, PMID 26934136, PMID 26951772, PMID 27694262, PMID 27978569, PMID 28082176, PMID 28130349, PMID 28492874, PMID 28923789, PMID 29800250, PMID 30194931, PMID 30646425, PMID 30674731, PMID 31215818, PMID 31592954, PMID 32352493, PMID 33098644, PMID 33230035, PMID 33497524, PMID 34006508, PMID 34185708, PMID 34219679, PMID 34629400, PMID 35129211, PMID 35695006, PMID 36154908, PMID 36166771, PMID 36240084, PMID 37172884, PMID 37418643
2018 (4), 2016 (2), 2009 (1), 2014 (1), M01RR000054 (1), M01RR000070 (1), R01AA029606 (1), R21DK113487 (1), R24EY022023 (1), U10EY011751 (1), U10EY017281 (1), U10EY017387 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1)